Traws Pharma (NASDAQ:TRAW) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients [Yahoo! Finance]
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
Traws Pharma (NASDAQ:TRAW) was upgraded by analysts at Zacks Research to a "hold" rating.
Traws Pharma (NASDAQ:TRAW) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $8.00 price target on the stock.